DY
TCON

Dowling & Yahnke’s TRACON Pharmaceuticals, Inc. Common Stock TCON Stock Holding History

Dowling & Yahnke’s Portfolio TCON Stock Details TCON Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		$79K Hold
2,373
– – ﹤0.01% 365
2022
Q2 		$95K Hold
2,373
– – ﹤0.01% 367
2022
Q1 		$125K Hold
2,373
– – 0.01% 368
2021
Q4 		$131K Buy
2,373
+350
+17% +$22.3K 0.01% 368
2021
Q3 		$157K Hold
2,023
– – 0.01% 364
2021
Q2 		$263K Hold
2,023
– – 0.02% 322
2021
Q1 		$333K Buy
2,023
+500
+33% +$96.3K 0.02% 281
2020
Q4 		$356K Hold
1,523
– – 0.03% 271
2020
Q3 		$157K Buy
1,523
+500
+49% +$26.8K 0.01% 298
2020
Q2 		$40K Buy
1,023
+273
+36% +$10.8K ﹤0.01% 297
2020
Q1 		$26K Buy
+750
New +$43.6K ﹤0.01% 289

Other funds holding TCON

OM
Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
LA
Linden Advisors New York $19.3B AUM 1.47% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.6B AUM 109.3% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
TI
Telemetry Investments New York $63.3M AUM 0.06% 1-Year Est. Return

Dowling & Yahnke's TCON Position: Q3 2022 in Review

Dowling & Yahnke held its TRACON Pharmaceuticals, Inc. Common Stock (TCON) position steady in Q3 2022 at 2,373 shares worth $79K. The position accounts for ﹤0.01% of the portfolio, ranked #365.

Dowling & Yahnke first reported a position in TCON in Q1 2020 and has held it in 11 quarters since. The position peaked at $356K in Q4 2020. 33 funds tracked by Wall St. Rank hold TCON as of Q3 2022.

  • Dowling & Yahnke held 2,373 shares of TRACON Pharmaceuticals, Inc. Common Stock worth $79K as of Q3 2022.
  • Dowling & Yahnke left its TRACON Pharmaceuticals, Inc. Common Stock share count unchanged in Q3 2022.
  • TRACON Pharmaceuticals, Inc. Common Stock made up ﹤0.01% of Dowling & Yahnke's portfolio in Q3 2022, its #365 holding.
  • Dowling & Yahnke first reported a position in TRACON Pharmaceuticals, Inc. Common Stock in Q1 2020 and has held it in 11 quarters since.
  • Dowling & Yahnke's TRACON Pharmaceuticals, Inc. Common Stock position peaked at $356K in Q4 2020.
  • 33 funds tracked by Wall St. Rank held TRACON Pharmaceuticals, Inc. Common Stock as of Q3 2022.

Based on Dowling & Yahnke's 13F filing for Q3 2022, filed 3 Nov 2022.